Can I Take Melatonin with Spironolactone?

The Short Answer: Are They Safe Together?

Melatonin and spironolactone do not share a known direct pharmacokinetic interaction. Neither drug meaningfully alters the metabolism of the other through cytochrome P450 pathways at typical clinical doses. What does exist is a pharmacodynamic overlap: both agents can lower blood pressure through separate mechanisms, and melatonin's influence on insulin secretion adds a layer of metabolic complexity that matters specifically for women with PCOS.

For the majority of women taking spironolactone at 25 to 100 mg/day for hormonal acne or PCOS-related androgenism, taking 0.5 to 3 mg of melatonin at bedtime is unlikely to cause a clinically significant problem. The risk profile shifts if your spironolactone dose is higher, if you already have low blood pressure, or if you are managing insulin resistance alongside your hormonal condition.

Why Women Ask This Question More Than Men

Spironolactone is used far more commonly in women than men for dermatologic and endocrine indications. ACOG guidelines support its use for hyperandrogenism in PCOS, and it is one of the most prescribed off-label agents for hormonal acne in reproductive-age women. Sleep disruption is also more prevalent in women, particularly during perimenopause, the luteal phase of the menstrual cycle, and the postpartum period, which is why women on spironolactone are disproportionately likely to reach for a melatonin supplement.

How Spironolactone Works in Women

Spironolactone is a potassium-sparing diuretic and aldosterone antagonist that also blocks androgen receptors. At the doses used for PCOS, hirsutism, and hormonal acne (typically 50 to 200 mg/day), its blood pressure-lowering effect is real but usually modest. A 2023 review in the Journal of the American Academy of Dermatology confirmed that spironolactone at 100 mg/day reduces systolic blood pressure by approximately 3 to 5 mmHg in normotensive women.

Sex-Specific Pharmacokinetics

Women metabolize spironolactone differently from men. Women have a lower volume of distribution for spironolactone's active metabolite canrenone, which means plasma concentrations can run higher at equivalent weight-based doses. Data from pharmacokinetic studies show that the area under the curve for canrenone is roughly 30 to 40 percent greater in women than in men after an equivalent oral dose. This is one reason dosing for androgenic indications in women starts low (25 mg) and titrates slowly.

How the Menstrual Cycle Affects Blood Pressure on Spironolactone

Aldosterone levels rise naturally in the luteal phase (days 14 to 28 of a typical cycle). Because spironolactone blocks aldosterone, its blood-pressure-lowering effect may be slightly more pronounced in the second half of your cycle. Women who add melatonin during this phase may notice more dizziness on standing, a point rarely covered in standard prescribing information.

How Melatonin Works and Where It Overlaps

Melatonin is an endogenous pineal hormone that regulates circadian rhythm. Exogenous melatonin at supplement doses is generally considered low-risk, but it is not inert. Two physiological effects matter most when you are also taking spironolactone.

Effect 1: Blood Pressure Modulation

Melatonin has a dose-dependent hypotensive effect, partly through nitric oxide-mediated vasodilation and partly through central sympatholytic activity. A meta-analysis of 17 randomized controlled trials published in the Journal of Hypertension found that prolonged-release melatonin (2 mg nightly for 3 weeks) reduced systolic blood pressure by a mean of 6 mmHg in patients with nocturnal hypertension. Add that to spironolactone's antihypertensive effect and the combined reduction is additive, not synergistic, but still worth tracking if your baseline blood pressure is already on the lower side.

Effect 2: Glucose and Insulin Secretion

This is the more nuanced concern for women with PCOS. Melatonin receptors (MT1 and MT2) are expressed in pancreatic beta cells. Melatonin binding suppresses insulin secretion at night, which is physiologically normal. A genome-wide association study published in Nature Genetics identified a variant in the MTNR1B gene (encoding the MT2 receptor) that associates with fasting glucose elevation and increased type 2 diabetes risk. Women with PCOS already carry a substantially elevated risk of insulin resistance. The Endocrine Society's 2023 clinical practice guideline on PCOS estimates that 50 to 70 percent of women with PCOS have some degree of insulin resistance regardless of body weight.

Taking exogenous melatonin may transiently blunt overnight insulin secretion and nudge fasting glucose upward. This effect is probably small at doses of 0.5 to 1 mg but is less well characterized at the 5 to 10 mg doses found in many over-the-counter supplements in the United States. A randomized crossover trial in Obesity found that 10 mg nightly melatonin over 12 weeks raised fasting glucose by approximately 4 mg/dL in adults with overweight or obesity, a modest but directionally unfavorable signal for women already managing metabolic risk.

A Practical Framework for Women With PCOS Taking Both

Spironolactone and melatonin each affect PCOS biology from different angles. Spironolactone lowers androgens. Melatonin, in some research, reduces ovarian oxidative stress and may modestly improve oocyte quality, which is why some reproductive endocrinologists have explored it in fertility contexts. But the interaction at the metabolic level (insulin suppression plus the already-impaired glucose disposal common in PCOS) means that women with PCOS and insulin resistance should check fasting glucose at their next lab visit after starting melatonin, not just assume that a "natural" supplement carries no metabolic footprint.

If you are on metformin alongside spironolactone for PCOS-related insulin resistance, melatonin's glucose effect is probably blunted but still worth monitoring.

Is the Interaction Pharmacokinetic or Pharmacodynamic?

This distinction matters because pharmacokinetic interactions (where one drug changes how the other is absorbed, distributed, metabolized, or excreted) are generally harder to predict and manage than pharmacodynamic interactions (where two drugs affect the same physiological endpoint through separate pathways).

The melatonin-spironolactone interaction is pharmacodynamic. Melatonin is primarily metabolized by CYP1A2. Spironolactone and its active metabolites are metabolized through CYP3A4 and CYP2C8, with some involvement of sulfotransferases. These pathways do not meaningfully compete with each other at standard doses. No published pharmacokinetic study has demonstrated that melatonin alters spironolactone plasma levels, or vice versa.

The clinically meaningful overlaps are:

• Additive blood pressure lowering (both agents independently reduce systolic BP)
• Possible exacerbation of insulin secretion suppression overnight (relevant to PCOS and prediabetes)
• Additive sedation at higher melatonin doses (spironolactone itself is not sedating, but the combination with 5 to 10 mg melatonin can leave some women feeling groggy the next morning)

Does Melatonin Affect Androgens? Implications for Spironolactone Users

There is early-stage evidence that melatonin modulates the hypothalamic-pituitary-gonadal axis. A small randomized trial in Reproductive Biology and Endocrinology found that 3 mg/night of melatonin over 6 months reduced total testosterone by a statistically significant margin in women with PCOS compared to placebo. The mechanism is not fully established, but reduced LH pulsatility and direct ovarian effects are both proposed.

If this effect is real and replicable, it means melatonin may modestly add to spironolactone's anti-androgenic work. That could be a benefit (faster reduction in hirsutism or acne) or a consideration worth tracking if you develop symptoms of androgen suppression beyond what your prescriber expected.

The evidence here is preliminary. The trial above enrolled only 40 women and used a single dose. Larger, well-powered studies in women are needed before this can be called a confirmed effect.

Life-Stage Considerations

Reproductive Years (Ages 18 to 40)

This is the most common demographic on spironolactone for hormonal acne and PCOS. The blood pressure interaction is usually manageable. The glucose concern is real if you carry PCOS-related insulin resistance. Contraception is essential on spironolactone (see Pregnancy section below), and melatonin does not interact with oral contraceptives at the pharmacokinetic level, though estrogen-containing pills do raise endogenous melatonin levels by inhibiting CYP1A2.

Trying to Conceive

Spironolactone must be stopped before attempting conception (see Pregnancy section). Melatonin has been studied in fertility settings, and some reproductive endocrinologists prescribe it off-label as an antioxidant adjunct during IVF cycles. A 2021 meta-analysis in Fertility and Sterility found that melatonin supplementation before oocyte retrieval was associated with higher rates of mature oocytes but did not reach statistical significance for live birth rates. Once you stop spironolactone and shift to conception mode, melatonin's profile changes entirely.

Perimenopause

Sleep disruption is nearly universal in perimenopause, and hormonal acne frequently resurges due to estrogen and progesterone fluctuations. Women in their 40s are often on both spironolactone and melatonin simultaneously. Blood pressure also becomes more variable in perimenopause. Check your blood pressure at home in the morning if you are adding melatonin to an existing spironolactone regimen, particularly in the first two weeks.

Postmenopause

Spironolactone prescriptions for androgenic alopecia (female pattern hair loss) are common in postmenopausal women. Blood pressure tends to be higher with age, but individual variability is wide. If you are on an antihypertensive in addition to spironolactone, adding melatonin triples the potential for additive hypotension and warrants a conversation with your prescriber.

Pregnancy, Lactation, and Contraception

This section is required reading if you are of reproductive age.

Spironolactone in Pregnancy

Spironolactone is contraindicated in pregnancy. It is classified as a teratogen in animal models, where it feminizes male fetuses through anti-androgenic effects. Human data are limited, but the FDA label for spironolactone explicitly states it should not be used during pregnancy. Because spironolactone is prescribed almost exclusively to women of reproductive age for dermatologic and endocrine indications, contraception is not optional. ACOG recommends that women of reproductive age taking spironolactone use reliable contraception throughout treatment.

A combined oral contraceptive pill is often co-prescribed, which also offers additive androgen-blocking benefit (particularly pills containing drospirenone or norgestimate). If you are using a progestin-only method, discuss this explicitly with your prescriber, as some progestins have androgenic activity that may partially offset spironolactone's effect.

If you become pregnant while on spironolactone, stop the medication and contact your OB-GYN immediately.

Melatonin in Pregnancy

Melatonin is not classified under the traditional FDA pregnancy category system for supplements. Human safety data in pregnancy are limited. A 2022 review in the American Journal of Obstetrics and Gynecology noted that endogenous melatonin rises significantly in the third trimester and may play a role in fetal circadian programming, but it concluded that evidence is insufficient to recommend exogenous melatonin supplementation in pregnancy. Avoid melatonin in pregnancy unless directed by your OB-GYN.

Lactation

Spironolactone passes into breast milk in small amounts. The LactMed database at the NIH classifies spironolactone as probably compatible with breastfeeding at low doses, with monitoring of the infant for signs of electrolyte disturbance. Melatonin is also present in breast milk naturally and its endogenous concentration peaks at night. Exogenous supplementation would add to this load. Human data on supplemental melatonin during lactation are insufficient to establish safety, and most clinicians recommend avoiding it until more data are available.

Who This Is Right For and Who Should Be More Cautious

Lower-Risk Profile

You are likely in a lower-risk category for the melatonin-spironolactone combination if you:

• Take spironolactone at 25 to 75 mg/day for hormonal acne or mild hirsutism
• Have normal blood pressure (systolic above 110 mmHg consistently)
• Do not have insulin resistance or prediabetes
• Plan to use a dose of 0.5 to 1 mg melatonin (the lowest effective dose for most women)
• Are between 18 and 40 years old with no cardiovascular history

Higher-Risk or Use-With-Caution Profile

Discuss this combination with your prescriber before starting if you:

• Take spironolactone at doses of 100 mg or above
• Already have low blood pressure or take other antihypertensives
• Have PCOS with confirmed insulin resistance, prediabetes, or elevated fasting glucose
• Are perimenopausal or postmenopausal (blood pressure variability increases)
• Are considering doses of melatonin above 3 mg
• Take other supplements that lower blood pressure (magnesium, CoQ10 at high doses, berberine)

Practical Guidance: What to Do If You Are Already Taking Both

Most women who discover they are already taking melatonin alongside spironolactone do not need to stop either medication immediately. The interaction is pharmacodynamic and manageable.

Take these steps:

1. Check your blood pressure at home in the morning for the first two weeks. Readings consistently below 90/60 mmHg warrant a call to your prescriber.
2. Use the lowest effective melatonin dose. Start at 0.5 mg and increase only if sleep does not improve. A meta-analysis in PLOS ONE found that doses as low as 0.5 mg were as effective as higher doses for sleep onset latency in healthy adults.
3. Time melatonin appropriately. Take it 30 to 60 minutes before your intended sleep time. Spironolactone is typically taken once daily in the morning with food to reduce diuretic effect overnight. Separating them by 8 or more hours minimizes any overlap in blood pressure effects.
4. Get a fasting glucose at your next lab draw if you have PCOS or any history of impaired glucose tolerance.
5. Tell your prescriber. Supplement use is consistently under-reported. Melatonin's blood pressure effect is relevant to any clinician managing your spironolactone dose.

The Evidence Gap: What We Do Not Know Yet

Women have been underrepresented in the pharmacokinetic and pharmacodynamic trials that inform supplement-drug interaction guidance. No published randomized controlled trial has directly studied melatonin co-administration in women taking spironolactone specifically. The glucose data from the MTNR1B work and the melatonin-insulin studies were not conducted in populations on spironolactone. The blood pressure meta-analysis data are generalizable, but they did not stratify by sex or hormonal status.

What we have is extrapolated reasoning from mechanistic data, not direct observation. That extrapolation supports the conclusion that the combination is manageable for most women, but it is not the same as a definitive safety declaration. Until better sex-stratified supplement interaction data exist, individual monitoring remains the most reliable safety tool.